IGC2026 北京站 | 会前专访系列2026年初,中国细胞治疗赛道迎来历史性一刻:石药集团自主研发的SYS6055注射液——国内首款获批临床的体内CAR-T产品——正式获批进入临床试验。这不仅意味着“在体内生成CAR-T”这一革命性构想在中国落地,更预示着细胞治疗从“个体化定制”向“规模化即时可用”的范式跃迁正在加速。站在“首个”的起点上,如何看待未来?IGC组委会非常有幸于IGC 2026 ...
Source LinkIGC2026 北京站 | 会前专访系列2026年初,中国细胞治疗赛道迎来历史性一刻:石药集团自主研发的SYS6055注射液——国内首款获批临床的体内CAR-T产品——正式获批进入临床试验。这不仅意味着“在体内生成CAR-T”这一革命性构想在中国落地,更预示着细胞治疗从“个体化定制”向“规模化即时可用”的范式跃迁正在加速。站在“首个”的起点上,如何看待未来?IGC组委会非常有幸于IGC 2026 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.